

# CORPUS - Observational Cohort on Rheumatology Practices and Uses

Head :Guillemin Francis, CIC-EC NANCY

Last update : 08/08/2014 | Version : 1 | ID : 60035

## General

### Identification

Detailed name Observational Cohort on Rheumatology Practices and Uses

Sign or acronym CORPUS

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation Accord CNIL : 14/11/2006

### General Aspects

Medical area Rheumatology

Others (details) Spondyloarthritis, juvenile arthritis

Keywords Quality of life, health, healthcare usage, resumption of activity, biotherapy treatment, side effects, switch

### Scientific investigator(s) (Contact)

Name of the director Guillemin

Surname Francis

Phone + 33 (0)3 83 85 21 63

Email francis.guillemin@chu-nancy.fr

Unit CIC-EC NANCY

Organization CHU

### Collaborations

### Funding

Funding status Private

Details	WYETH PHARMACEUTICALS FRANCE, SCHERING PLOUGH, ABBOTT FRANCE
<b>Governance of the database</b>	
Sponsor(s) or organisation(s) responsible	CHU Nancy
Organisation status	Public
<b>Additional contact</b>	
<b>Main features</b>	
<b>Type of database</b>	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Prospective Inclusion cut-off date: 01/02/2010 Other bodies active in creating this cohort: SFR DNFMI SFD
<b>Database objective</b>	
Main objective	General objective: to determine the impact of basic prescribed treatment with or without prescribed biotherapy, focussing on the impact of changes in biotherapy over time. Epidemiological recording of the occurrence of adverse events in the long term. Secondary objective: To investigate the role of biotherapy in patient treatment by determining its position in prescribed treatment order during therapeutic sequences.
Inclusion criteria	All patients that have never received biotherapy and are monitored in one of the participating centres: - patients with active rheumatoid arthritis (with or without prescription), DAS28 score greater than 3.2 regardless of disease onset age, with hand and feet x-rays in the last 3 months - active idiopathic

juvenile arthritis (JIA) (with or without prescription), following methrexate intolerance or failure, x-ray in the last 3 months - active (with or without prescription) spondyloarthritis (SPA) (ankylosing or psoriatic arthritis) regardless of disease onset age, pelvic and spinal x-ray in the last 3 months, or of hands and feet according to peripheral or axial form

## Population type

Age  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered Sick population

Gender  
Male  
Woman

Geography area National

Detail of the geography area Muticentric cohort throughout France (133 centres)

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY) 02/2007

Date of last collection (YYYY or MM/YYYY) 02/2012

### Size of the database

Size of the database (number of individuals) [500-1000[ individuals

Details of the number of individuals 640 (407 PAR, 192 SPA, 41 AJI)

### Data

Database activity Current data collection

Type of data collected Clinical data

Clinical data (detail) Direct physical measures  
Medical registration

Presence of a biobank	No
Health parameters studied	Quality of life/health perception
<b>Procedures</b>	
Data collection method	Self-administered questionnaire: optical input from a paper questionnaire Clinical examinations: optical input from a form Biological analysis: optical input from a paper form
Participant monitoring	Yes
Details on monitoring of participants	Follow-up duration: 5 years
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
<b>Access</b>	
Terms of data access (charter for data provision, format of data, availability delay)	Data may not be used by academic teams. Data may not be used by industrial teams.
Access to aggregated data	Access on specific project only
Access to individual data	No access